(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights Total gross of voting rights: 96,493,078 05/31/2024 96,493,078 Total net* of voting rights: 96,236,383 * Net total = total number of voting rights attached to shares – shares without voting rights Att ...

Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk pres ...

Core Viewpoint - DBV Technologies is actively participating in the EAACI 2024 Congress to present its research on Viaskin Peanut, focusing on its potential to treat peanut allergies in young children and the importance of understanding accidental peanut consumption during treatment [1][2][3]. Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company dedicated to developing treatment options for food allergies and other immunologic conditions, particularly through its proprietary Viaskin technology [7]. - The company aims to address significant unmet medical needs in food allergies, which affect millions, including young children [7]. Upcoming Events - DBV Technologies will present a flash talk on data from its EPITOPE Phase 3 study regarding accidental peanut consumption in toddlers aged 1 to 3 years during the EAACI Congress [2][5]. - The company will host a symposium titled "Epicutaneous Route: An Innovative Potential Approach to Food Immunotherapy," featuring expert lectures on the clinical applications of epicutaneous immunotherapy [3][6]. Research Focus - The company emphasizes the importance of establishing long-term safety and clinical data for Viaskin Peanut, particularly in pediatric populations, to understand the implications of accidental allergen exposure [3]. - DBV Technologies is conducting ongoing clinical trials for Viaskin Peanut in peanut-allergic toddlers and children, aiming to modify the immune response to allergens through epicutaneous immunotherapy [7]. Exhibition Details - DBV will have an exhibit booth (F10) at the EAACI Congress, where attendees can learn more about its ongoing clinical trials and the Viaskin technology [4].

As a result of the change in the ADS Ratio, DBV's ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be equal to or greater than twice the ADS trading price before the change. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focuse ...

No fractional new ADSs will be issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank. The ADS Ratio Change will have no impact on DBV's underlying ordinary shares, and no ordinary shares will be issued or cancelled in con ...

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the "Company"), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel ...

Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 1 ...

(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36697 DBV TECHNOLOGIES S.A. (Exact name of registrant as specified in its charter) State or other jurisdiction of incorporation ...

Exhibit 99.1 Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May ...

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the "Company"), will hold its Combined General Meeting (the "General Meeting") on May 16, 2024, a ...